1 / 3

IVD Antibody Development Services for CK-18 M30 Marker

With abundant experience in IVD (in vitro diagnostics) antibodies development, Creative Biolabs is able to provide a full range of CK-18 M30 marker antibodies development services for liver failure screening and therapeutic monitoring.

bellasmith12
Download Presentation

IVD Antibody Development Services for CK-18 M30 Marker

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. IVD Antibody Development Services for CK-18 M30 Marker With abundant experience in IVD (in vitro diagnostics) antibodies development, Creative Biolabs is able to provide a full range of CK-18 M30 marker antibodies development services for liver failure screening and therapeutic monitoring. Our professional team is optimized to help you with high-quality and cost-effective service to make your project a success. Cytokeratin 18 Neoepitope M30 (CK-18 M30) Chronic hepatitis B (CHB) infection is one of the most common causes of chronic liver disease worldwide. In CHB infection, liver histology may be normal, mild or moderately damaged, or cirrhotic. A serious increase in liver fibrosis is observed in the advanced stages of the disease. Serum apoptotic cytokeratin 18 neoepitope M30 (CK-18 M30) is among the popular noninvasive markers used to detect liver fibrosis. Hepatocyte apoptosis can be initiated by different complex pathways, most of which involve activation of the caspases. CK-18 is a major intermediate filament protein in liver cells and one of the most prominent substrates of caspases during hepatocyte apoptosis. CK-18 M30, which is coded between the 387, 396th position of CK-18 is produced by caspase system activation and accepted as an apoptosis marker. Altered degradation and increased synthesis of extracellular matrix (ECM) proteins are implicated in liver fibrosis.

  2. Fig.1 CK18 is cleaved at Asp238 and Asp396 by caspases during apoptosis. (Olofsson, MH., 2007) CK-18 M30 Marker of Liver Failure CK-18 M30 has been a popular marker for detecting liver fibrosis in recent years. It becomes available at an early caspase cleavage event during apoptosis and has been regarded as a biochemical marker of liver injury. Serum M30 levels is a potential biomarker of severe liver disease in nonalcoholic fatty liver disease (NAFLD) and normal aminotransferase levels. It has also been identified as a useful marker associated with increased severity of fibrosis and inflammation in chronic hepatitis C (CHC) and nonalcoholic fatty liver disease (NAFLD). M-30 antigens are at least 10-fold greater in acute liver failure (ALF) patients compared to patients with chronic HCV or normal controls. Levels of the liver- specific apoptosis marker M-30 antigen were significantly higher in patients who died or needed liver transplantation than those who survived spontaneously.

  3. Fig.2 CK-18 neoepitope (M30 antigen) levels are significantly increased in the serum of NASH patients in comparison to patients with SS and controls. (Yaman, E., 2010) CK-18 M30 Marker Antibodies IVD antibodies are extensively used for disease screening, therapeutic monitoring, and immunology methods such as immunonephelometry and sandwich ELISA. Through our role as a leading antibody IVD company, Creative Biolabs is well-positioned to deliver a focused product to the research market representing the highest value targets for the diagnosis and prognosis of liver failure. Creative Biolabs has focused on IVD antibodies discovery for years. We have experts who are able to develop high-affinity IVD antibodies against varies of markers. We are therefore confident in offering the most suitable service and finest results for our customers all over the world. If you are interested in our IVD antibodies discovery services, please contact us for more details. References 1. Yaman, E., (2010). “Serum M30 levels are associated with survival in advanced gastric carcinoma patients.”Int Immunopharmacol 10(7): 719-722. 2. Olofsson, MH., (2007). “Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy.”Clin Cancer Res 13(11): 3198-3206. Related Services: IVD Antibody Development Services for HGF Marker IVD Antibody Development Services for IL-6 Marker

More Related